Item 4 — Purpose of Transaction
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The Reporting Persons continuously evaluate their investment in the Issuer, and, from time to time, engage in discussions with the Issuer's management with respect to the Issuer's strategic direction, business opportunities, financing, and other matters. On December 30, 2024, upon the recommendation of the Reporting Persons, the Issuer appointed Jason Richey to serve on the Issuer's board of directors (the "Board"), effective as of December 30, 2024. The appointment was made in anticipation of the Omnibus Amendment between the Issuer, RTW Investments, and the other parties thereto, dated as of January 7, 2025 (as described below in Item 6 of this Amendment No. 4). The Reporting Persons believe that Mr. Richey's significant experience in the medical device industry, knowledge and experience with respect to leading medical device companies, financing and strategic initiatives, will provide valuable leadership and strategic guidance to the Board and the Issuer's management. Mr. Richey currently serves as a consultant to RTW Investments. Item 6 of the Schedule 13D is hereby incorporated by reference.